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The eﬀects of keishibukuryogan on the early stage of progressive renal failure were examined in rats subjected to 5/6 nephrectomy.
Keishibukuryogan, one of the traditional herbal formulations, was given orally at a dose of 1% (w/w) and 3% (w/w) in chow.
Administration of keishibukuryogan was started at 1 week after 5/6 nephrectomy and was continued for 4 weeks. At the end
of the experiment, Azan staining did not reveal any severe histological changes in the kidneys of the nephrectomized rats. On
the other hand, signiﬁcant increases in mRNA expressions of transforming growth factor-β1 and ﬁbronectin related to tissue
ﬁbrosis, as examined by Reverse Transcriptase-Polymerase Chain Reaction, were observed in nephrectomized rats, and they were
signiﬁcantly suppressed by 3% keishibukuryogan treatment. Against gene expressions related to macrophage inﬁltration, 3%
keishibukuryogan treatment signiﬁcantly suppressed osteopontin mRNA levels, and monocyte chemoattractant protein-1 and
vascular cell adhesion molecule-1 mRNA levels showed a tendency to decrease, but without statistical signiﬁcance. It was also
observed that 3% keishibukuryogan attenuated serum urea nitrogen and urinary protein excretion levels. From these results, it
was suggested that keishibukuryogan exerts beneﬁcial eﬀects that result in slowing the progression of chronic renal failure.
1.Introduction
Chronicrenalfailure(CRF)isoneoftheserioushealthprob-
lems that are linked to increasing incidence and prevalence
as well as a reduction in the quality of life and a rise in the
cost of its care. Current therapy with agents that block the
renin-angiotensin system and exert protein restriction are
commonly employed management strategies of renal failure
[1].However,thenumberofpatientswithrenalfailure,espe-
cially patients undergoing hemodialysis and facing end-stage
renal failure, is increasing worldwide. Therefore, searches for
new eﬀective therapeutic approaches are needed for CRF,
including the use of alternative medicines such as traditional
herbal medicine.
TraditionalChinese/Japanesemedicinehasalonghistory
and has contributed to the prevention and treatment of
various diseases. Keishibukuryogan was ﬁrst mentioned
in “Kinki-Yohryaku” (Jin-Gui-Yao-Lue), a classic text of
Chinese medical science written in the 3rd century AD.
Keishibukuryogan has been widely administered to patients
with blood stagnation for improving blood circulation,
and is now one of the most frequently used prescriptions
in Japan. It was reported that keishibukuryogan improves
conjunctional microcirculation in patients with cerebro-
spinal vascular diseases [2], suggesting the contribution of
its improving eﬀects on hemorheological parameters such as
blood viscosity, RBC aggregability and RBC deformability
[3–5]. Moreover, Matsumoto et al. [6]h a v ee x p l o r e da
proteomic approach for the diagnosis of blood stasis in
rheumatoidarthritispatientstreatedwithkeishibukuryogan.
In animal experiments, keishibukuryogan was reported to
prevent the progression of atherosclerosis, and to preserve
vascular endothelial function in cholesterol-fed rabbits and
in diabetic rats [7, 8]. Recently, keishibukuryogan was
revealed to suppress ﬁbronectin deposition associated with
transforming growth factor-β1 (TGF-β1) in the kidney of
diabetic rats [9]. In this connection, to unearth additional
possible eﬀects of keishibukuryogan on CRF, we conducted2 Evidence-Based Complementary and Alternative Medicine
the present study to examine its eﬀects on the early stage of
renal failure induced by 5/6 nephrectomy.
2. Methods
2.1. Test Drug. Powdered keishibukuryogan was purchased
from Uchida Wakanyaku (Tokyo, Japan). It is composed of
equalparts,byweight,ofthe followingﬁvecrudedrugs:Cin-
namomi Cortex, bark of Cinnamomum cassia Blume (Lau-
raceae);Poria,sclerotiumofPoriacocosWolf(Polyporaceae);
Moutan Cortex, bark of Paeonia suﬀruticosa Andrews (Paeo-
niaceae); Persicae Semen, kernel of Prunus persica Batsch
(Rosaceae) and Paeoniae Radix, root of Paeonia lactiﬂora
Palas (Paeoniaceae). These crude drugs were mixed and
shattered by grinding machine. Figure 1 shows the 3D HPLC
chart of keishibukuryogan. The HPLC conditions were as
follows: keishibukuryogan extract (2.5g) was obtained with
20ml of methanol under ultrasonication for 30min. The
solution was passed though a membrane ﬁlter (0.45μm)
and then subjected to HPLC analysis. HPLC equipment was
controlled with an SLC-10A (Shimadzu, Tokyo, Japan) using
a TSK-GEL ODS-80TS column (4.6ψ ×250mm), eluting
with solvents (A) 0.05M AcONH4 (pH 3.6) and (B) CH3CN.
A linear gradient of 100% A and 0% B, changing over 60min
to 0% A and 100% B, was used. The ﬂow rate was controlled
with an LC-10AD pump at 1.0ml min−1.T h ee l u a t ef r o m
the column was monitored, and 3D data were processed by
SPD-M10A diode array detectors. All assigned peaks were
identiﬁed by co-injection test with authentic samples and
compared with UV spectral data.
2.2.AnimalsandDrugTreatments. Six-week-oldmaleWistar
rats were purchased from Japan SLC Inc. (Hamamatsu,
Japan) and kept in an automatically controlled room
(temperature about 23◦C and humidity about 60%) with
a conventional dark/light cycle. At the age of 7 weeks, 5/6
nephrectomy was performed under anesthesia with sodium
pentobarbital (50mgkg−1 body weight, i.p.) by ablation
of approximately 2/3 of the left kidney, and then removal
of the right kidney by ligation of renal artery, vein and
ureter 1 week later. As adaptive response to the renal
ablation, remnant kidney undergo hypertrophy, resulting in
glomerular hyperﬁltration and hypertension, and proceed
proteinuria, azotemia and renal ﬁbrosis with glomerular
sclerosis and tubulointerstitial scarring over time [10, 11].
After recovery from the operation (after 1 week), the animals
were divided into three groups (a control and two treatment
groups), avoiding any inter-group diﬀerences in blood urea
nitrogen levels. A normal group of rats having undergone a
sham operation was also included. During the experimental
period, the normal (n = 5) and control (n = 15) groups were
fed a standard chow, and the other two groups (n = 12, resp.)
were fed a standard chow containing keishibukuryogan at a
dose of 1% w/w or 3% w/w. The consumption of diet was
kept at the same amount (30grat−1 day−1). After 4 weeks of
treatment, the rats were sacriﬁced and blood samples were
obtained. Tissues were quickly frozen and kept at −80◦C
until analysis.
All experimental procedures were performed in accor-
dance with the standards established by the “Guide for the
Care and Use of Laboratory Animals at the University of
Toyama.”
2.3. Analysis of Serum and Urine Samples. Serum levels of
creatinine and urea nitrogen were determined using com-
mercial kits (CRE-EN Kainos and BUN Kainos purchased
from Kainos Laboratories, Inc., Tokyo, Japan). Urinary pro-
tein content was determined using commercial kits (Micro
TP-test, Wako Pure Chemical, Osaka, Japan).
2.4. Reverse Transcriptase-Polymerase Chain Reaction (RT-
PCR). Total RNA was extracted using the RNeasy Mini Kit
(QIAGEN K.K., Tokyo, Japan). cDNA was synthesized from
2μg of total RNA using an oligo dT primer (Invitrogen,
Tokyo, Japan) and reverse transcriptase (SuperScript II,
Invitrogen). PCR was performed using reverse transcription
products (cDNA), each primer and a TAKARA Ex Taq PCR
kit (Takara Shuzo Co. Ltd., Kyoto, Japan). The sequences of
primers and PCR conditions are shown in Table 1. cDNA
was ampliﬁed using a Thermal Cycler (Perkin-Elmer Cetus,
Foster City, CA, USA). The number of cycles were predeter-
mined for each pair of primers in order to avoid the PCR
plateau phase. The parallel expression of glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) mRNA was tested as an
internal standard. The PCR products were analyzed in 1.5%
agarose gel along with a 100bp DNA ladder, and the bands
were scanned using a computer analysis system (H.P. Scan
jet 4P and ATTO Densitograph ver. 4) and normalized to the
corresponding GAPDH mRNA signal from the same sample.
2.5. Histological Study. For light microscopy, tissues were
ﬁxed with formalin (10%) and embedded in paraﬃn. Two
μm sections were stained with Azan stain, and the extent of
tubulointerstitial changes was estimated.
2.6. Statistical Analysis. All values were presented as
mean±SE, and were analyzed by one-way analysis of
variance (ANOVA) followed by Dunnett’s test. P <.05 were
accepted as statistically signiﬁcant.
3. Results
3.1. Body and Kidney Weights. Changes in body and kidney
weights are summarized in Table 2. The body weight of
5/6 nephrectomized rats was signiﬁcantly lower than that
of the normal rats. Body and kidney weights did not diﬀer
among the three nephrectomized groups, that is, control, 1%
keishibukuryogan and 3% keishibukuryogan groups.
3.2. Renal Function. Table 3 shows the eﬀects of keish-
ibukuryogan on renal functional parameters. Compared
with the normal group, the control group had signiﬁcantly
increased serum urea nitrogen and creatinine levels. Treat-
ment with keishibukuryogan did not change the serum cre-
atinine levels, but the 3% keishibukuryogan group showed a
signiﬁcant reduction in serum urea nitrogen compared withEvidence-Based Complementary and Alternative Medicine 3
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Figure 1: Three-dimensional HPLC proﬁle of MeOH extract of keishibukuryogan. Glc, β-d-glucopyranosyl; Gal, galloyl.
Table 1: Summary of primer sequences, PCR conditions and size of ampliﬁed fragments.
Genes Orientation Sequences (5  to 3 ) Annealing Size
MCP-1 Sense GCC AGA TCT CTC TTC CTC CA 62◦C, 60s 432bp
Antisense GAG GTG GTT GTG GAA AAG AG
VCAM-1 Sense CTG ACC TGC TCA AGT GAT GG 60◦C, 50s 260bp
Antisense GTG TCT CCC TCT TTG ACG CT
Osteopontin Sense AGA GGA GAA GGC GCA TTA CA 61◦C, 60s 498bp
A n t i s e n s e G C AA C TG G GA T GA C CT T GA T
TGF-β1
Sense TAC AGG GCT TTC GCT TCA GT 61◦C, 60s 394bp
Antisense TGG TTG TAG AGG GCA AGG AC
Fibronectin Sense TTA TGA CGA CGG GAA GAC CTA 56◦C, 60s 295bp
Antisense GGC TGG ATG GAA AGA TTA CTC
GAPDH Sense GTG AGG TGA CCG CAT CTT CT 56◦C, 60s 278bp
Antisense TGG AAG ATG GTG ATG GGT TT
MCP-1,monocytechemoattractantprotein-1;VCAM-1,vascularcelladhesionmolecule-1;TGF-β1,transforminggrowthfactor-β1;GAPDH,glyceraldehyde-
3-phosphate dehydrogenase.
the control group. Similarly, the urinary protein content in
the 3% keishibukuryogan group was reduced signiﬁcantly.
3.3. RT-PCR. Figure 2 shows the eﬀects of keishibukuryo-
gan on renal mRNA levels of monocyte chemoattrac-
tant protein-1 (MCP-1), vascular cell adhesion molecule-
1 (VCAM-1), osteopontin, TGF-β1 and ﬁbronectin. In
nephrectomized control rats, signiﬁcant increases in MCP-
1, osteopontin, TGF-β1 and ﬁbronectin expressions were
observed compared with normal rats. The administration of
3% keishibukuryogan signiﬁcantly suppressed osteopontin,
TGF-β1 and ﬁbronectin mRNA levels, while it showed a
tendency to decrease MCP-1 and VCAM-1 mRNA levels
without statistical signiﬁcance.4 Evidence-Based Complementary and Alternative Medicine
Table 2: Eﬀects of keishibukuryogan on body and tissue weights.
Group Body weight (g) Kidney weight
(g/100g BW)
Normal rats 349±14
Nephrectomized rats
Control 314±22∗ 0.381±0.062
1% keishibukuryogan 317±17∗ 0.348±0.040
3% keishibukuryogan 319±21∗ 0.371±0.049
Statistical signiﬁcance: ∗P <.05 versus normal rats.
3.4. Histological Examination. At 5 weeks after 5/6 nephrec-
tomy, relatively mild tubulointerstitial ﬁbrosis was observed
(Figures 3(b)–3(d)). Such areas were virtually absent in the
normal group (Figure 3(a)). Tubular dilation was observed
in the 5/6 nephrectomized groups (Figures 3(b)–3(d)); there
were no obvious diﬀerences among these groups.
4. Discussion
The 5/6 nephrectomy model, a well-characterized model of
CRF, features proteinuria and renal dysfunction in associ-
ation with glomerulosclerosis and tubulointerstitial ﬁbrosis
[12], and has been widely used to investigate the eﬀects
of therapeutic strategies and the pathogenic mechanisms of
progressive renal failure.
Among the renal structural changes, tubulointerstitial
ﬁbrosis is known to be a common histological appearance
in patients with CRF, and it is thought to be correlated
with the decline of renal function and prognosis [13, 14].
It was reported that tubulointerstitial ﬁbrosis is severe at
12 weeks after 5/6 nephrectomy, with large areas displaying
tubular dilation, intratubular cast formation and tubular
atrophy, and that it was relatively mild at 3 and 6 weeks after
5/6 nephrectomy [15]. Similar results were observed in the
present study, with mild tubulointerstitial ﬁbrosis at 5 weeks
after 5/6 nephrectomy being the only change compared
with normal rats, and keishibukuryogan treatment also
showed similar features. Additionally, glomerular sclerosis
and arteriolar hyalinosis were inconspicuous in the three
nephrectomy groups. So, it indicates that severe structural
changes did not develop at this point (Figure 3).
The pathogenesis of the development of CRF includes
macrophage inﬁltration [16]. Macrophages are known to
participate in inﬂammatory reaction, producing a variety
of cytokines and growth factors [17]. Many studies have
reported that the number of macrophages as revealed
by immunostaining for ED1 increased remarkably in the
remnant kidney of rats subjected to 5/6 nephrectomy
[16, 18–20], and it was also observed that macrophage
inﬁltration and proliferation occurs early (2–4 weeks after
surgery), preceding the development of glomerulosclero-
sis and tubulointerstitial ﬁbrosis [16, 18, 21]. On the
other hand, the reduction of inﬂammatory cell inﬁltra-
tion with some agents was reported to be associated
with the prevention of progressive renal failure [22, 23].
Therefore, it is considered that macrophage inﬁltration is
one of the most important events, preceding the devel-
opment of severe renal injury, and that the suppression
of macrophage inﬁltration would be a useful therapeutic
approach.
The inﬁltration of macrophages is induced by the
upregulation of cell adhesion molecules and chemokines.
From recent studies using several animal models such
as glomerulonephritis, unilateral ureteral obstruction, dia-
betic nephropathy and 5/6 nephrectomy [22, 24–27], the
expressions of MCP-1, VCAM-1 and osteopontin have been
shown to be elevated. Additionally, increases of these gene
expressions have been suggested to contribute to renal
damage by promoting macrophage inﬁltration. Therefore,
in this study, we focused on the early stage of progressive
renal failure before the development of severe renal injury,
and examined whether keishibukuryogan could suppress
the gene expressions associated with macrophage recruit-
ment in the remnant kidney of rats at 5 weeks after
5/6 nephrectomy. Our results showed that the adminis-
tration of 3% keishibukuryogan signiﬁcantly suppressed
osteopontin mRNA levels. Osteopontin, a potent chemo-
tactic and adhesion molecule for monocyte/macrophage,
has been recently shown to have strong association with
focal macrophage inﬁltration in a number of experimental
models of renal injury, suggesting a pathologic role in
progressive renal injury [28–30]. Keishibukuryogan also
induced a decreasing tendency in both MCP-1 and VCAM-
1 mRNA expressions, although not statistically signiﬁ-
cant. These results suggest that keishibukuryogan treatment
inhibits macrophage inﬁltration by suppression of mRNA
levels related to macrophage recruitment, although further
studies are needed to clarify whether keishibukuryogan
suppress the macrophage inﬁltration by immunostaining for
ED1.
Accumulation of extracellular matrix (ECM) proteins, a
conspicuous ﬁnding accompanying the progression of renal
failure, is also included in the pathogenesis of progressive
renal failure [31, 32]. Kliem et al. [19] reported that
progressive interstitial accumulation of ECM proteins such
as ﬁbronectin, type IV collagen and laminin occurred,
in parallel with monocyte/macrophage inﬂux, in the 5/6
nephrectomized model. Macrophages may participate in
the development of ﬁbrosis by the release of ﬁbrogenic
cytokines such as TGF-β1 and interleukin-1 [33]. TGF-
β1 has been implicated as playing a central role in the
regulation of the overdeposition of ECM proteins [32, 34].
Immunohistochemical examination TGF-β1 and ﬁbronectin
expressions has shown their increase predominantly along
ﬁbrous tissue in the remnant kidney of 5/6 nephrectomized
rats [35]. Furthermore, increased TGF-β1 mRNA expression
has been observed at 4 weeks, and was sustained at 12
weeks after 5/6 nephrectomy [25]. From these ﬁndings,
suppression of TGF-β1 and ECM protein overdeposition is
also thought to be a useful therapeutic approach. Previously,
we demonstrated that keishibukuryogan suppressed TGF-β1
and ﬁbronectin protein expressions in the kidney of diabetic
rats [9]. Therefore, we examined their gene expressions in
the remnant kidney of 5/6 nephrectomized rats. Our resultsEvidence-Based Complementary and Alternative Medicine 5
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Figure 2: Eﬀects of keishibukuryogan on mRNA levels in the remnant kidney of nephrectomized rats. (a) Typical example of each PCR
product, (b) MCP-1, (c) VCAM-1, (d) osteopontin, (e) TGF-β1 and (f) ﬁbronectin mRNA expression relative to normal rats. Statistical
signiﬁcance: ∗P <.05, ∗∗P <.01 versus normal rats, #P <.05 versus nephrectomized control rats.
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Figure 3: Representative photomicrographs of Azan-stained section in normal rats (a), nephrectomized rats in the control (b), 1%
keishibukuryogan (c), 3% keishibukuryogan (d). Magniﬁcation 200X.6 Evidence-Based Complementary and Alternative Medicine
Table 3: Eﬀects of keishibukuryogan on biochemical parameters.
Group Serum urea nitrogen
(mgdl
−1)
Serum creatinine
(mgdl
−1)
Urinary protein excretion
(mgmg−1 Cr)
Normal rats 16.9±2.7 0.485±0.152 1.94±0.21
Nephrectomized rats
Control 35.6±4.5∗ 0.770±0.083∗ 2.79±0.52
1% keishibukuryogan 32.2±4.1∗ 0.769±0.068∗ 2.35±0.60
3% keishibukuryogan 29.3±4.9∗,### 0.738±0.081∗ 1.32±0.36#
Statistical signiﬁcance: ∗P <.01 versus normal rats, #P <.05, ##P < .01 versus nephrectomized control rats.
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Figure 4: Hypothetical representation of the eﬀects of keishibukuryogan on renal failure.
showed that keishibukuryogan treatment signiﬁcantly sup-
p r e s s e dm R N Al e v e l so fT G F - β1 and ﬁbronectin, suggesting
that keishibukuryogan exerts beneﬁcial eﬀects on the kidney
by inhibiting ECM protein accumulation induced by TGF-
β1, independently of the primary disease.
Oxidative stress is widely recognized to involve the
pathogenesis of CRF. As one of causal link to urinary protein
excretion and renal dysfunction, impairment of glomerular
basal membrane due to lipid peroxidation induced by
enhanced oxidative stress has been suggested [36]. Previ-
ously, we reported that keishibukuryogan decreased lipid
peroxidation and elevated superoxide dismutase activity in
the kidney [9, 37]. On the other hand, keishibukuryogan
has been demonstrated to improve blood circulation and
vasoendothelial disorders, and discussed the link to anti-
oxidative eﬀects of keishibukuryogan [7, 8, 38, 39], from the
viewpoint in which keishibukuryogan has been traditionally
used for improvement of blood stagnation syndrome. There-
fore, we speculate that keishibukuryogan improve oxidative
conditions and microcirculation in the kidney of CRF,
and these eﬀects may contribute, at least in parts, to the
attenuation of serum urea nitrogen and urinary protein
excretion.
The number of patients suﬀering from CRF is increasing
year by year. Interventions using angiotensin-converting
enzyme (ACE) inhibitors, angiotensin receptor blockers
and protein restriction, aimed at slowing the progres-
sion of CRF, are widely accepted. On the other hand, it
has also been reported that the use of ACE inhibitors
induced hyperkalemia, a life-threatening complication [40].
Keishibukuryogan has long been prescribed for patients,
and serious adverse reactions have not been reported.
Additionally, in the present study, body weight and survival
rate were not adversely aﬀected by the administration
of keishibukuryogan. As a result, keishibukuryogan has
widened expectations for its clinical application, although
further clinical trials on possible adverse reactions will still
be needed to ensure its safe use for patients with renal
dysfunction.
In summary, our present results provided evidence that
keishibukuryogan suppressed gene expressions associated
with macrophage inﬁltration and renal ﬁbrosis in the
remnant kidney of rats subjected to 5/6 nephrectomy,
preceding the development of severe renal failure. Moreover,
keishibukuryogan improved proteinuria and renal dysfunc-
tion. We summarized our hypothetical representation that
explain the eﬀects of keishibukuryogan on renal failure
(Figure 4). Although further experiments are called for
to deﬁnitively determine whether keishibukuryogan can
ameliorate the severe functional and structural changes that
takeplacelongitudinally after5/6nephrectomy,theresultsof
this study suggested that keishibukuryogan treatment at theEvidence-Based Complementary and Alternative Medicine 7
early stage of progressive renal failure is useful for slowing
down CRF progression.
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